| Today’s Big NewsSep 14, 2023 |
| By Gabrielle Masson Right after making headlines for a phase 3 mRNA flu shot win, Moderna shared that it’s axing four clinical assets from its pipeline—including two AstraZeneca dumped last year. |
|
|
|
| Philadelphia, PA |  |
|
|
By Eric Sagonowsky As British research supplies and tools provider Abcam moves toward a potential multibillion-dollar sale, one of the company's founders and major shareholders is pushing back. |
By Conor Hale Developed by the South Korea-based company Lunit, the Insight MMG program has previously collected green lights for use in the U.S. and Europe. |
By Fraiser Kansteiner J&J is uniting its medtech and pharmaceutical arms so that they will be “more connected to the Johnson & Johnson brand," the company said. Over time, Janssen is slated to become Johnson & Johnson Innovate Medicine, while the company’s medical technology segment will continue to run with the J&J MedTech moniker. |
|
Thursday, September 21, 2023 | 2pm ET / 11am PT In today's ever-evolving healthcare landscape, understanding and leveraging data to develop comprehensive insights is crucial to stay ahead. Specialty datasets, such as genomics, clinical, labs, and patient hub data, are critical to unlock deeper insights and improve healthcare data utilization, and it’s important to ensure these various sources of data seamlessly integrate. Register now to learn more. 
|
|
By Nick Paul Taylor Sanofi has handed First Wave BioPharma a chance to reposition a long-dormant molecule. The biotech is paying a “modest” upfront fee for capeserod as part of a deal that gives Sanofi the right of first refusal to buy the asset back. |
By Andrea Park In its latest attempt to weather the digital therapeutics storm, Akili is taking a different tack, one that will help it avoid having to rely on skeptical insurers altogether. |
By Angus Liu An FDA advisory committed voted in favor of Alnylam's bid to expand its RNA-silencing drug Onpattro into the rare heart disease called ATTR-CM. But comments at Wednesday’s panel suggest the drug could carry a disadvantage in its upcoming clash with Pfizer. |
By Nick Paul Taylor AbbVie has punctured Harpoon Therapeutics’ dream of a $200 million payday. Needing to pay the sum to take up its option on the anti-BCMA T-cell engager HPN217, AbbVie has opted against moving deeper into a space that is already congested with candidates including its own rival bispecific. |
By Andrea Park A new day has dawned for AWAK Technologies, the maker of a kidney dialysis machine so small that it can fit in a shoulder bag for on-the-go treatments. |
By Ben Adams Depicting the plight of patients with chronic and potentially fatal diseases is always a challenge for pharma companies, but Gilead Sciences has quite literally found a novel way forward. |
By Max Bayer As the TIGIT class gets closer to possible clinical success, Bristol Myers Squibb is trimming one of its candidates. |
By Zoey Becker The 15-year partnership with the U.K.'s Future Biogas will cut emissions by an estimated 20,000 tons of carbon dioxide. The deal provides AstraZeneca with enough renewable gas to supply around 8,000 homes. |
By Helen Floersh Scientists from leading research institutions called for standardized practices, greater public transparency and more in a new report on gain-of-function research, which comes as the White House deliberates a new framework for how such studies are regulated. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," we discuss the trends seen at Cannes Lions, the top compensated CEOs in the industry, and the cancer drug shortage |
|
|---|
|
|
|
Wednesday, September 27, 2023 | 11am ET / 8am PTIn the rapidly evolving field of drug discovery, where the COVID-19 pandemic has further accelerated changes in working patterns, the importance of efficient teamwork, open communication, and streamlined processes throughout the Design-Make-Test-Analyze (DMTA) cycle is essential. Technology holds the potential to address these challenges by improving collaboration. Register now to learn more. 
|
|
Whitepaper Learn more about how you can improve the productivity of your research and manufacturing operations and accelerate the journey from laboratory to saving lives. Sponsored by: JLL |
Whitepaper Learn how outsourcing the buffer preparation can reallocate resources to support core activities of your bioprocess production. Sponsored by: Thermo Fisher Scientific |
Whitepaper From trial site feasibility and patient populations to data analysis, generative AI has the potential to revolutionize drug discovery and clinical trial recruitment at both the therapeutic area and indication level. Sponsored by: H1 |
Whitepaper Learn how a GPCR-focused library with a cell-based biopanning strategy led to the discovery of 13 high-affinity and selective anti-GLP-1R antibodies with highly developable therapeutic properties. Sponsored by: Twist Bioscience |
Whitepaper By 2030, the global demand for biologics is projected to grow at a CAGR of 8.7% and the challenges, risks, and costs of bringing large molecule products to market are growing exponentially. Sponsored by: ThermoFisher Scientific |
Whitepaper 15 biotech executives from the Cambridge area discuss the current biotech landscape, as well as challenges, opportunities, and best practices for emerging biotech companies seeking success in the UK and beyond. Sponsored by: Blue Matter, strategic consultants in the life sciences |
Whitepaper Learn how process liquids and buffers impact your total cost of ownership (TCO) and how outsourcing can revolutionize your approach, ensuring quality standards and improving productivity. Sponsored by: Thermo Fisher Scientific Process Liquid Preparation Services |
| |
|
